Meaningful Evidence
Nevro’s unique PDN indication is the outgrowth of years of investments in clinical trials culminating with the SENZA-PDN, the largest RCT evaluating SCS for PDN to date.
The only commercially approved SCS system with a specific indication for Painful Diabetic Neuropathy.
Nevro’s unique PDN indication is the outgrowth of years of investments in clinical trials culminating with the SENZA-PDN, the largest RCT evaluating SCS for PDN to date.
Within the SENZA-PDN, 10 kHz Therapy demonstrated exceptional outcomes across responder rates, pain relief, and even sensory response.
Direct Neural Inhibition With
10 kHz Therapy
Historically, PDN patients have struggled with a lack of treatment options when CMM fails. Now, 10 kHz Therapy and a unique mechanism of action offer new potential for relief.
*
HFX is a comprehensive solution that includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain. Throughout this presentation HFX™ for PDN means that a patient has been implanted with a Senza System and programmed to include a frequency of 10 kHz.